16 / 08 / 2026
KKR to Acquire Medtech Manufacturer Integer in $5.7bn Deal
By Precious Jorge
This week’s key terms/concepts:
• Private Equity (PE): A financial model where firms pool investor capital to buy companies, optimise their operations and financials, and sell them for a profit.
• Take-private deal (or public-to-private transaction / P2P): The shares of a public company that has been bought is traded on an exchange, then it is removed from public trading to function privately.
• Enterprise Value: The total value of a company during an acquisition, which includes the cost to buy all stocks, plus any debt assumed by the buyer.
As of last week, global investment firm KKR has officially entered into a definitive agreement to acquire Integer Holdings Corporation in an all-cash take-private transaction valued at approximately $5.7 billion, including the assumption of debt. Under the terms of the acquisition, Integer stockholders will receive $127 per share, representing a 51.8% premium to the company’s stock price on April 29, 2026, when Integer announced a comprehensive strategic review following pressure from activist investor Irenic Capital Management. Integer is one of the world’s largest contract development and manufacturing organisations for the medical technology sector. The transaction is expected to close by the end of 2026, after which Integer will be delisted from the New York Stock Exchange and operate as a privately held company.
Why is this important?
This deal signals that large private equity firms remain willing to commit billions to healthcare, even in an otherwise cautious buyout market. Integer sits at the centre of the medtech supply chain, manufacturing components that device makers rely on rather than build in-house, and the price KKR is paying reflects confidence in that outsourced model.
The transaction is also a clear example of activist pressure accelerating a sale. Irenic Capital Management’s intervention pushed Integer’s board towards a strategic review. Within months that review produced a buyout at a substantial premium, a fast, certain return for shareholders rather than a longer path as an independent company.
Taking Integer private gives KKR more room to invest for the long term, away from the quarterly scrutiny of public markets, though the deal’s scale and Integer’s role in the supply chain may still draw regulatory attention.
What does this mean for law firms?
The scale of the transaction will drive high-value work across several practice areas. Davis Polk & Wardwell is advising Integer and Kirkland & Ellis is advising KKR, underlining how central corporate M&A and private equity teams are to negotiating and closing take-private deals of this size, alongside finance lawyers structuring KKR’s debt package and antitrust specialists reviewing the deal’s competitive impact.
Attention now turns to shareholder and regulatory approval, with a close targeted by the end of 2026.